Objective To investigate allele frequency distributions and haplotype polymorphism of ten Y-chromosome short tandem repeats (STR) loci of Han population in Zhuhai area and evaluate their applicability to forensic cases. Methods DYS393, DYS19, DYS389 Ⅱ, DYS390, DYS391, DYS389 Ⅰ, DYS439、DYS438、DYS392 and DYS385 loci were amplified with Y-plex~(TM) PCR amplification Kit and analyzed by ABI 310 genetic analyzer. 200 unrelated male individuals of Han nationality in Zhuhai were recruited for determination of allele frequencies and haplotype data. Results 5, 6, 6, 5, 4, 5, 5, 5, and 7 alleles were found in 9 of the 10 Y-STR loci, respectively and 44 haplotypes were detected at DYS385 locus. The range of gene diversity (GD) was determined between 0.3904 for DYS391 and 0.9497 for DYS385. Total 161 haplotypes were found at the 10 Y-STR loci, of which 134 occurred once, 20 occurred twice, 3 occurred three times, 3 occurred four times, and 1 occurred five times. The cumulative GD was 0.9948. Conclusion The 10 Y-STR loci are highly polymorphic and suitable for forensic individual identification and paternity testing in Zhuhai Han population.

Objective To develop a highly sensitive luminescent reagent for bloodstain testing at forensic crime scenes.Methods Based ontheprincipleof ECL luminescence and the ping-pong conjugate activation principle of chemical electronic chain,this project developed a new type of highly sensitive luminescent reagent for bloodstain testing by usingthe uniform design of experimental methods to optimize the conditions andsynthesize several new compounds.Results The bloodstain testing luminescent reagentdeveloped in this project has high sensitivity andlongluminescence time.In the case of blood samples diluted by 1,000 times,reading the fluorescence withChemiScope 3300 chemiluminescence imaging system,the maximumvalue of gray scale reached 56,and the luminescence time lasted for 10 minutes.Conclusion The project has successfully developed a highly semitivebloodstain testing reagentthat could be applied to crime scene investigation.

Since the outbreak of coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) discovered in December 2019, the disease has emerged as a global pandemic (Shi et al., 2020; World Health Organization, 2020). Several studies have shown a higher incidence of COVID-19, as well as related poor outcomes in patients with malignancies as compared with those without them (Liang et al., 2020; Tian et al., 2020). The impact of cancer on COVID-19 may be attri‑buted to the use of antitumor treatments that may disturb the host response to SARS-CoV-2 infection (Wang et al., 2020), while the current studies on this topic have drawn controversial conclusions. Some implied that anticancer treatments might elevate the risk of death (García-Suárez et al., 2020; Liu et al., 2020). On the contrary, others pointed out that this association is not significant (Brar et al., 2020; Lee et al., 2020a). Although previous systematic reviews have investigated this important issue (Wang and Huang, 2020), the heterogeneity of findings is obvious and the general conclusion has remained unclear. Considering this ambiguity, it is difficult for clinicians to make therapeutic decisions when facing patients with both cancer and COVID-19; therefore, a high-quality and accurate evaluation of the impact of anticancer treatments on COVID-19 patients is necessary. Accordingly, we conducted a pooled analysis with the original data of each patient for the first time to provide a comprehensive perspective into the association between anticancer regimens and the outcomes of cancer patients with COVID-19.
Adult ; Aged ; Aged, 80 and over ; COVID-19/complications* ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/therapy* ; SARS-CoV-2